PCNA
Labelling as a Proliferative Marker
in Gynaecological Tumours
1203-1208
Correspondence
ALKA (Asst. Prof)
M.D. Pathology,
Dept. of Pathology
Adesh Medical College & Hosptial
Bhatinda, Punjab, India.
Phone: 09464482556
E-mail: gupta.dralka@yahoo.com
Aim: The aim was to study the expression of PCNA in gynaecological tumours and to correlate PCNA expression with types and grades of different gynaecologica tumours.
Materials & Methods: Biopsies from 60 cases of gynaecologica tumours were subjected to Haematoxylin and eosin (H&E) stain and PCNA (proliferating cell nuclear antigen) immunostaining. PCNA scoring was done on each case.
Results: Out of 60 cases, 30 cases (50%) were of cervical lesions, 15 cases (25%) were of endometrial tumours and 15 cases (25%) were of ovarian tumours. In cervical lesions 20 cases (66.6%) were squamous cell carcinoma and positivity was observed with different PCNA proliferative scores. Most of the CIN (cervical intraepithelial neoplasia) cases had low PCNA score and most of the cervical squamous cell carcinomas had a high PCNA score. Among 15 cases endometrial carcinomas, 9 cases (15%) were well differentiated type, 3 cases (5%) were moderately differentiated type and 3 cases (5%) were poorly differentiated type. Of 15 ovarian tumours, 10 cases(16%) were of serous cystadenocarcinoma, 3 cases (5%) were of mucinous cystadenocarcinoma and 2 cases (3%) were of undifferentiated type.
Conclusion: PCNA expression along with other markers in different tumours can be used to predict the proliferative activity of the tumour and subsequent prognosis. It can also be helpful in differentiating cervical intraepithelial neoplasia and squamous cell carcinoma of cervix. The application of PCNA proliferative activity may provide information regarding the clinical stage and histological grade of malignant epithelial ovarian tumours and endometrial adenocarcinomas.